Abstract
Cisplatin is a clinically important antineoplastic agent with particular usefulness in the treatment of testicular and ovarian cancer. The cure rate for patients with advanced testicular cancer has increased to 70–80% with cisplatin-based combination regimens (1). In patients with advanced ovarian cancer, cisplatin-based combination chemotherapy has increased complete response rates and prolonged overall survival compared to single agent therapy (2). However, due to the development of acquired drug resistance, the majority of patients with bulky ovarian cancer are not cured with standard dose cisplatin regimens. It has been shown that the dose of cisplatin is a critical factor in achieving optimum results in patients with either testicular or ovarian cancer. However, the toxicity of cisplatin (primarily nephrotoxicity) has prevented the routine administration of doses >100–120 mg/m2.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Einhorn, L.H. Cancer Res. 41: 3275–3280, 1981.
Ozols, R.F. and Young, R.C. Semin. Oncol. 12: 21–30, 1985.
Behrens, B.C., Hamilton, T.C., Masuda, H., Grotzinger, K.R., Whang-Peng, J., Louie, K.G., Knutsen, T., McKoy, W.M., Young, R.C. and Ozols, R.F. Cancer Res. 47: 414–418, 1987.
Hamilton, T.C., Young, R.C, Louie, K.G., Behrens, B.C., McKoy, W.M., Grotzinger, K.R. and Ozols, R.F. Cancer Res. 44: 5286–5290, 1984.
Ozols, R.F., Deisseroth, A.B., Messerschmidt, J. Cancer 51: 1803–1807, 1983.
Ozols, R.F., Ostchega, Y., Myers, C.E. and Young, R.C. J. Clin. Oncol. 3: 1246–1250, 1985.
Ozols, R.F., Ostchega, Y., Curt, G. and Young, R.C. J. Clin. Oncol. 5: 197–201, 1987.
Reed, ET, Yuspa, S.H., Zwelling, L.A., Ozols, R.F. and Poirier, M.C. J. Clin. Inv. 77: 545–550, 1986.
Ozols, R.F. and Young, R.C. In: Current Problems in Cancer (Ed. C.M. Haskell), Year Book Medical Publishers, No. 11, Chicago, 1987, in press.
Ozols, R.F., Ihde, D. and Jacob, J. Proc. Amer. Soc. Clin. Oncol. 6: 107, 1987.
Ozols, R.F., Corden, B.J., Jacob, J., Wesley, M.N., Ostchega, Y. and Young, R.C. Ann. Int. Med. 100: 19–24, 1984.
Reed, E., Ozols, R.F., Tarone, R., Yuspa, S.H. and Poirier, M.C. Proc. Natl. Acad. Sci. USA 84: in press, 1987.
Louie, K.G., Behrens, B.C., Kinsella, J.J., Hamilton, T.C., Grotzinger, K.R., McKoy, W.M., Winker, M.A. and Ozols R.F. Cancer Res. 45: 2110–2115, 1985.
Hamilton, T.C., Masuda, H., Young, R.C. and Ozols, R.F. Proc. Amer. Assoc. Cancer Res. 28: 291, 1987.
Hamilton, T.C., Winker, M.A., Louis, K.G., Batist, G., Behrens, B.C., Tsuruo, T., Grotzinger, K.R., McKoy, W.M., Young, R.C. and Ozols, R.F. Biochem. Pharmacol. 34: 2583–2586, 1985.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Ozols, R.F. et al. (1988). High Dose Cisplatin and Drug Resistance: Clinical and Laboratory Correlations. In: Nicolini, M. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Developments in Oncology, vol 54. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1717-3_21
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1717-3_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8967-8
Online ISBN: 978-1-4613-1717-3
eBook Packages: Springer Book Archive